NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R61/R33 Clinical Trial Required)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

Next predicted deadline: Dec 8, 2023 (Letter of inquiry)

Later predicted deadlines: Jan 7, 2024 (Full proposal)

Grant amount: US $250,000 - US $1,515,000

Funding uses: Research

Location of project: Anywhere in the world

Location of residency: United States

Overview:

NOTE: All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates: June 4, 2023 and October 2, 2023. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates: January 7, 2023, September 7, 2023, and January 7, 2024.

The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This FOA will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.